Clinical Trials
Phase 1 Dose Escalation Study of COM902 in Patients with Advanced Malignancies
This study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of escalating doses of COM902, an anti-TIGIT antibody, monotherapy in patients with advanced malignancies who have exhausted all available standard therapies.
Proof-of-Concept Studies of COM701+COM902+pembrolizumab in metastatic microsatellite stable colorectal cancer and platinum resistant ovarian cancer
Two proof of concept studies designed to evaluate the simultaneous blockade of three immune checkpoint pathways, PVRIG (COM701), TIGIT (COM902) and PD-1 (pemrolizumab), in patients with metastatic microsatellite stable colorectal cancer and platinum resistant ovarian cancer. These studies are building on prior data suggesting that blocking PVRIG may sensitize tumors to respond to PD-1 and TIGIT blockade, and could turn cold tumors hot, potentially offering a chemotherapy free option to patients. This is a real potential opportunity to transform the lives of patients with the right immunotherapy combinations.
Rilvegostomig
Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, that is in Phase 2 development by AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies.
Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01)
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)
The Phase 1 study sponsored and conducted by Bayer evaluating the safety and tolerability of BAPOTULIMAB in patients with advanced solid tumors is active and not recruiting.
Phase 1 Study of bapotulimab in Patients
with Advanced Solid Tumors
This Bayer sponsored study which is active, not recruiting is designed to evaluate the safety and tolerability of bapotulimab , an anti-ILDR2 antibody licensed to Bayer by Compugen, in a dose escalation study as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. An expansion study is active, not recruiting is designed to evaluate the combination of bapotulimab with pembrolizumab in head and neck squamous cell carcinoma.
Bayer resolved to terminate, effective as of February 27, 2023, the parties’ research and development collaboration and license agreement. Bayer will retain the right to continue to provide patients with bapotulimab to the extent required.
Compugen plans to execute its right to receive an exclusive license under Bayer’s intellectual property as required to allow it to continue the development and commercialization of bapotulimab, to the extent it will choose to do so.
Phase 1 Study of BAY 1905254 in Patients with Advanced Solid Tumors
This Bayer sponsored study is designed to evaluate the safety and tolerability of BAY 1905254, an anti-ILDR2 antibody licensed to Bayer by Compugen, in a dose escalation study as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. An expansion study is designed to evaluate the combination of BAY 1905254 with pembrolizumab in head and neck squamous cell carcinoma.
Rilvegostomig
Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, that is in Phase 2 development by AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies.
Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01)
